文献速递泌尿生殖与妇科肿瘤放疗

二甲双胍预防接受根治性放疗的前列腺癌患者雄激素剥夺治疗所致人体测量学与代谢并发症:一项II期随机对照试验

Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2022-07-28

本II期多中心随机对照试验将83例接受根治性放疗联合雄激素剥夺治疗(ADT,18-36个月)的血糖正常局部晚期前列腺癌患者按1:1随机分配至二甲双胍500 mg口服每日3次(30-36个月)组或安慰剂组。中位随访23个月,二甲双胍组5个月时平均体重较基线变化低于安慰剂组(-1.80 kg,P=0.038),但1年时无显著差异(+0.16 kg,P=0.874);腰围增加两组均存在,二甲双胍未显著减轻(1年:安慰剂组+2.79 cm vs 二甲双胍组+1.46 cm,P=0.336)。结论:二甲双胍未显著减轻ADT所致人体测量学与代谢并发症。

要点

  • 二甲双胍组5个月时平均体重变化较安慰剂组低-1.80 kg(P=0.038),但1年时无显著差异(+0.16 kg,P=0.874)。
  • 1年时腰围变化安慰剂组+2.79 cm vs 二甲双胍组+1.46 cm,差异无统计学意义(P=0.336)。
  • 5个月时LDL胆固醇二甲双胍组-0.32 mmol/L vs 安慰剂组-0.03 mmol/L(P=0.022),1年时无显著差异(-0.17 mmol/L vs -0.19 mmol/L,P=0.896)。

核心结论

  • 接受根治性放疗联合ADT的男性随时间推移体重增加且腰围增大,二甲双胍未显著减轻这些变化。
  • 本研究未观察到二甲双胍对ADT所致人体测量学与代谢并发症的预防作用,二甲双胍仍在III期随机对照试验中评估其潜在抗肿瘤作用。

研究设计与样本

  • II期多中心随机对照试验,将83例接受根治性放疗联合ADT(18-36个月)的血糖正常局部晚期前列腺癌患者按1:1随机分配至二甲双胍500 mg口服每日3次(30-36个月)组或相同安慰剂组。
  • 研究入组时间为2015年12月至2019年10月,中位随访23个月。

主要发现

  • 队列基线平均体重指数(BMI)为30.2(范围22.2-52.5)。
  • 5个月时平均体重较基线变化二甲双胍组低于安慰剂组(-1.80 kg,P=0.038),但更长随访时无显著差异(1年:+0.16 kg,P=0.874)。
  • 两组接受ADT者腰围均增加,二甲双胍未显著减轻这些变化(1年:安慰剂组+2.79 cm vs 二甲双胍组+1.46 cm,P=0.336)。
  • 5个月时LDL胆固醇二甲双胍组(-0.32 mmol/L)低于安慰剂组(-0.03 mmol/L)(P=0.022),但更长随访时差异无显著意义(1年:-0.17 mmol/L vs -0.19 mmol/L,P=0.896)。
  • HbA1C、甘油三酯、高密度脂蛋白(HDL)胆固醇和总胆固醇按研究组无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Patients with prostate cancer undergoing treatment with radical radiation therapy (RT) plus androgen deprivation therapy (ADT) experience a constellation of deleterious metabolic and anthropometric changes related to hypogonadism that are associated with increased morbidity and mortality. We assessed the effect of metformin versus placebo to blunt the adverse effects of ADT on body weight, waist circumference, and other metabolic parameters. METHODS AND MATERIALS: This phase 2, multicenter, randomized controlled trial (RCT) randomized normoglycemic men with locally advanced prostate cancer receiving radical RT and ADT (18-36 months) in a 1:1 ratio to receive metformin 500 mg by mouth 3 times a day (for 30-36 months) versus identical placebo. RESULTS: From December 2015 to October 2019, 83 men were randomized with median follow-up of 23 months. Baseline mean body mass Index (BMI) of the cohort was 30.2 (range 22.2-52.5). Change in mean weight relative to baseline was lower among men who received metformin compared with placebo at 5 months (-1.80 kg, P = .038), but was not significant with longer follow-up (1 year: +0.16 kg, P = .874). Although participants on ADT had increases in waist circumference in both study arms, metformin did not significantly reduce these changes (1 year: +2.79 cm (placebo) versus +1.46 cm (metformin), P = .336). Low-density lipoprotein (LDL) cholesterol was lower in the metformin arm (-0.32 mmol/L) compared with the placebo arm (-0.03 mmol/L) at 5 months (P = .022), but these differences were not significant with longer follow-up (1 year: -0.17 mmol/L vs -0.19 mmol/L, P = .896). There were no differences in HbA1C, triglyceride, high-density lipoprotein (HDL) cholesterol, and total cholesterol by study arm. CONCLUSIONS: Men receiving radical RT and ADT gained weight and had increases in waist circumference over time that metformin did not significantly mitigate. Although this study did not observe any preventive effect of metformin on the anthropometric and metabolic complications of ADT, metformin continues to be studied in phase 3 RCTs in this patient population to assess its potential antineoplastic effects.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Usmani N, Ghosh S, Sanghera KP, et al. Metformin for Prevention of Anthropometric and Metabolic Complications of Androgen Deprivation Therapy in Prostate Cancer Patients Receiving Radical Radiotherapy: A Phase II Randomized Controlled Trial. Int J Radiat Oncol Biol Phys. 2022. PMID: 35907513. doi:10.1016/j.ijrobp.2022.07.035

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。